PRESS RELEASE : MorphoSys Concludes a USUSD 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma

DGAP-News: MorphoSys AG / Key word(s): Capital Increase 
MorphoSys Concludes a USUSD 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma 
2021-07-16 / 19:22 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Media Release 
MorphoSys Concludes a USUSD 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma 
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys") today announced that its Management Board, with the approval of the 
Supervisory Board, has passed a resolution to increase the share capital of MorphoSys AG by issuing 1,337,552 new 
ordinary shares from the Authorized Capital 2021-II, excluding pre-emptive rights of existing shareholders, to 
implement the purchase of 1,337,552 new ordinary shares by Royalty Pharma Investments 2019 ICAV, a subsidiary of 
Royalty Pharma plc (NASDAQ: RPRX) ("Royalty Pharma"). The new ordinary shares represent 3.9% of the registered share 
capital of MorphoSys following the capital increase. 
"We're pleased that Royalty Pharma is taking an equity position in MorphoSys as part of the long-term strategic finance 
partnership the two companies entered into this year," said Sung Lee, Chief Financial Officer of MorphoSys. 
Royalty Pharma's share purchase in the aggregate amount of USUSD 100 million is part of the funding agreement with 
MorphoSys for the now completed acquisition of Constellation Pharmaceuticals; the agreement has become effective upon 
the completion of the merger on 15 July 2021. Royalty Pharma has purchased the 1,337,552 new ordinary shares at a price 
of EUR 63.35 per share, the volume-weighted average price of MorphoSys shares five trading days on the Frankfurt Stock 
Exchange (Xetra) prior to the merger, representing a premium of 12.1% to today's closing market price on the Frankfurt 
Stock Exchange (Xetra). The new MorphoSys shares will be listed on the Frankfurt Stock Exchange. Royalty Pharma has 
agreed, subject to limited exceptions, not to sell or otherwise transfer any of the new ordinary shares for a period of 
twelve months. 
About MorphoSys 
MorphoSys (FSE & NASDAQ: MOR) is a biopharmaceutical company dedicated to the discovery, development and 
commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading 
expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has 
created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya^(R) 
(guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment 
of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In 
July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product 
Monjuvi^(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. 
Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. 
and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or 
www.morphosys-us.com. 
Monjuvi^(R) is a registered trademark of MorphoSys AG. 
Tremfya^(R) is a registered trademark of Janssen Biotech, Inc. 
Forward Looking Statements 
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The 
forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and 
involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and 
liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic 
or future results, financial conditions and liquidity, performance or achievements expressed or implied by such 
forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, 
and the development of the industry in which it operates are consistent with such forward-looking statements, they may 
not be predictive of results or developments in future periods. Among the factors that may result in differences are 
that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, 
clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on 
collaborations with third parties, estimating the commercial potential of its development programs and other risks 
indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. 
Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on 
such forward-looking statements. These forward-looking statements speak only as of the date of publication of this 
document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document 
to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on 
which any such statement is based or that may affect the likelihood that actual results will differ from those set 
forth in the forward-looking statements, unless specifically required by law or regulation. 
MorphoSys Contacts 
Investor Contact 
Dr. Julia Neugebauer 
Senior Director 
Tel: +49 (0)89 / 899 27 179 
[e-mail] 
Myles Clouston 
Senior Director 
Tel: [phone] 
[e-mail] 
Media Contact 
Thomas Biegi 
Vice President 
Tel.: +49 (0)89 / 89927 26079 
[e-mail] 
Jeanette Bressi 
Director, US Communications 
Tel: [phone] 
[e-mail] 
=---------------------------------------------------------------------------------------------------------------------- 
2021-07-16 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      MorphoSys AG 
              Semmelweisstr. 7 
              82152 Planegg 
              Germany 
Phone:        [phone] 
Fax:          [phone] 
E-mail:       [e-mail] 
Internet:     www.morphosys.com 
ISIN:         DE0006632003 
WKN:          663200 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq 
EQS News ID:  1219725 
 
End of News   DGAP News Service 
=------------ 

1219725 2021-07-16

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1219725&application_name=news

(END) Dow Jones Newswires

July 16, 2021 13:22 ET (17:22 GMT)